

DAFTAR PUSTAKA

1. The Global Cancer Observatory. *Global Burden of Cancer Study (Globocan) 2020.*; 2020. <https://gco.iarc.fr/today>.
2. Culp MBB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. *Eur Urol.* 2020;77(1):38-52. doi:10.1016/j.eururo.2019.08.005
3. Ding X, Cui FM, Xu ST, et al. Variants on ESR1 and their association with prostate cancer risk: A meta-analysis. *Asian Pacific J Cancer Prev.* 2012;13(8):3931-3936. doi:10.7314/APJCP.2012.13.8.3931
4. Zhao ZY, San M, Duprey JLHA, Arrand JR, Vyle JS, Tucker JHR. Detection of single nucleotide polymorphisms within a sequence of a gene associated with prostate cancer using a fluorophore-tagged DNA probe. *Bioorganic Med Chem Lett.* 2012;22(1):129-132. doi:10.1016/j.bmcl.2011.11.053
5. Wang YM, Liu ZW, Guo JB, Wang XF, Zhao XX, Zheng X. ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-Analysis. *PLoS One.* 2013;8(6). doi:10.1371/journal.pone.0066999
6. McIntyre MH, Kantoff PW, Stampfer MJ, et al. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. *Cancer Epidemiol Biomarkers Prev.* 2007;16(11):2233-2236. doi:10.1158/1055-9965.EPI-07-0481
7. Sivoňová MK, Dobrota D, Dušenka R, et al. Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population. *Mol Biol Rep.* 2012;39(8):7871-7880. doi:10.1007/s11033-012-1631-y
8. Low YL, Taylor JI, Grace PB, et al. Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. *Nutr Cancer.* 2006;56(1):31-39. doi:10.1207/s15327914nc5601_5
9. Sun T, Lee G-SM, Werner L, et al. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. *Cancer Epidemiol Biomarkers Prev a Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol.* 2010;19(7):1871-1878. doi:10.1158/1055-9965.EPI-10-0216
10. Onsory K, Sobti RC, Al-Badran AI, et al. Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. *Mol Cell Biochem.* 2008;314(1-2):25-35. doi:10.1007/s11010-008-9761-1
11. Bosland MC, Mahmoud AM. Hormones and prostate carcinogenesis: Androgens and estrogens. *J Carcinog.* 2011;10:33. doi:10.4103/1477-3163.90678
12. Cancer - 2011 - Salonia - Circulating estradiol but not testosterone is a significant predictor of high-grade prostate.pdf.
13. Ozten N, Vega K, Liehr J, et al. Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats. *Horm Cancer.* 2019;10(2-3):77-88. doi:10.1007/s12672-019-00360-7
14. Furic L, Lawrence MG, Risbridger GP. Pro-tumorigenic role of ER α in prostate cancer cells. *Aging (Albany NY).* 2015;7(6):356-357. doi:10.18632/aging.100769



15. McPherson SJ, Hussain S, Balanathan P, et al. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. *Proc Natl Acad Sci U S A*. 2010;107(7):3123-3128. doi:10.1073/pnas.0905524107
16. Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor beta (ER β) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. *Prostate*. 2003;54(2):79-87. doi:https://doi.org/10.1002/pros.10171
17. Bonkhoff H, Berges R. The Evolving Role of Oestrogens and Their Receptors in the Development and Progression of Prostate Cancer. *Eur Urol*. 2009;55(3):533-542. doi:https://doi.org/10.1016/j.eururo.2008.10.035
18. Horvath LG, Henshall SM, Lee CS, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. *Cancer Res*. 2001;61(14):5331-5335.
19. Quintas-Granados LI, Cortés H, Carmen MG Del, et al. The high methylation level of a novel 151-bp CpG island in the ESR1 gene promoter is associated with a poor breast cancer prognosis. *Cancer Cell Int*. 2021;21(1):1-11. doi:10.1186/s12935-021-02343-7
20. Royuela M, Miguel MP De, Bethencourt FR, Fraile B, Arenas MI, Paniagua R. Estrogen receptors and in the normal, hyperplastic and carcinomatous human prostate. *J Endocrinol*. 2001;447-454. doi:10.1677/joe.0.1680447
21. Toivanen R, Shen MM. Prostate organogenesis: Tissue induction, hormonal regulation and cell type specification. *Dev*. 2017;144(8):1382-1398. doi:10.1242/dev.148270
22. Coleman WB. *Molecular Pathogenesis of Prostate Cancer*. Second Edition. Elsevier Inc.; 2018. doi:10.1016/B978-0-12-802761-5.00025-0
23. Ahmed M, Eeles R. Germline genetic profiling in prostate cancer: Latest developments and potential clinical applications. *Futur Sci OA*. 2016;2(1). doi:10.4155/fso.15.87
24. Edge SB, American Joint Committee in Cancer. *AJCC Cancer Staging Manual*. 8th editio. New York: Springer; 2017.
25. Rezaeilouyeh H, Mahoor MH. Automatic gleason grading of prostate cancer using shearlet transform and multiple kernel learning. *J Imaging*. 2016;2(3). doi:10.3390/jimaging2030025
26. Chae YK, Huang HY, Strickland P, Hoffman SC, Helzlsouer K. Genetic polymorphisms of estrogen receptors α and β and the risk of developing prostate cancer. *PLoS One*. 2009;4(8). doi:10.1371/journal.pone.0006523
27. Zazzo E Di, Galasso G, Giovannelli P, Donato M Di. Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications. *Front Oncol*. 2018;8(January):1-7. doi:10.3389/fonc.2018.00002
28. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: Evidence for association with risk and histopathological tumor characteristics in Iranian men. *Mol Carcinog*. 2012;51(SUPPL. 1). doi:10.1002/mc.21870
29. Bonkhoff H. Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression. *Prostate*. 2018;78(1):2-10. doi:10.1002/pros.23446



30. Leach DA, Powell SM, Bevan CL. New roles for nuclear receptors in prostate cancer. *Endocr Relat Cancer*. 2016;23(11):T85-T108. doi:10.1530/ERC-16-0319
31. Takizawa I, Lawrence MG, Balanathan P, et al. Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. *Oncotarget*. 2014;6(2). doi:10.18632/oncotarget.2820
32. Yeh C-R, Da J, Song W, Fazili A, Yeh S. Estrogen receptors in prostate development and cancer. *Am J Clin Exp Urol*. 2014;2(2):161-168. <http://www.ncbi.nlm.nih.gov/pubmed/25374919> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4219301>.
33. Modugno F, Weissfeld JL, Trump DL, et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. *Clin cancer Res an Off J Am Assoc Cancer Res*. 2001;7(10):3092-3096.
34. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2008;22(5):1512-1520. doi:10.1096/fj.07-9526com
35. Mishra S, Tai Q, Gu X, et al. Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer. *Oncotarget*. 2015;6(42):44388-44402. doi:10.18632/oncotarget.6317
36. Kim SK, Chung JH, Park HC, et al. Association between polymorphisms of estrogen receptor 2 and benign prostatic hyperplasia. *Exp Ther Med*. 2015;10(5):1990-1994. doi:10.3892/etm.2015.2755